Octacosanol

Octacosanol

1. Identity: Chemical Names, Natural Sources, and Common Forms

Chemical Identity

1-Octacosanol (also known as n-octacosanol, octacosyl alcohol, cluytyl alcohol, and montanyl alcohol) is a straight-chain aliphatic 28-carbon primary fatty alcohol that is common in the epicuticular waxes of plants. Its molecular formula is C₂₈H₅₈O. Due to the presence of a hydroxyl group and a long aliphatic carbon chain, it exhibits distinctive physicochemical properties, including low water solubility, a high melting point, and excellent chemical stability. Its CAS number is 557-61-9, and its IUPAC structural formula is rendered as CH₃(CH₂)₂₆CH₂OH.

Octacosanol possesses extremely pure, spiny, or snowflake-shaped white crystals that are impervious to moisture, smell, heat, acid, alkali, and other environmental factors. Different purities display a variety of physical characteristics. The melting point ranges from 83.2°C when purity is greater than 97%. The substance's specific gravity at 85°C is 0.783 g/cm³, and its boiling point is 227°C at 100 Pa atmospheric pressure.

Relationship to Policosanol

In nature, octacosanol rarely exists in its free form. Instead, it is typically found as a component of policosanol, a mixture of long-chain aliphatic alcohols. Policosanol is composed of aliphatic primary alcohols with a chain length varying from 24 to 34 carbon atoms. Most policosanol preparations contain aliphatic alcohols in the following proportions: 66–67% octacosanol, 12–14% triacosanol, 7–8% hexacosanol, and 11–15% other carbon alcohols.

Natural Sources

The main natural sources of octacosanol include sugarcane wax, wheat germ oil, rice bran oil, and beeswax. These substances are commonly located in the waxy coating of plant epidermal layers, where they play a crucial role in forming the plant's external protective shield. Small quantities of octacosanol are available in the human diet through plants, mainly as a wax in the superficial layers of fruits, leaves, skins of common plants, and whole seeds. Additional sources identified in the scientific literature include grape seed oil, krill, perilla, and tomatoes.

The straight-chain alcohol with 28 carbon atoms was first extracted from wheat germ oil and identified to have a potential therapeutic effect on human reproductive disorders. Since only very small amounts are ingested in human or animal diets, octacosanol must be externally supplied to gain health benefits.

Commercial Forms and Preparations

With advances in natural product extraction and purification technologies, octacosanol can now be efficiently isolated from complex plant matrices. Commercial supplement preparations include:

• Standalone octacosanol capsules or tablets (typically standardized to a stated percentage of pure octacosanol)
• Policosanol supplements (mixtures of very long-chain aliphatic alcohols in which octacosanol is the dominant fraction)
• Wheat germ oil softgels or liquid preparations (which naturally contain octacosanol alongside vitamin E and other constituents)
• Rice bran oil extracts

Policosanol is naturally present in esterified form; however, during extraction from natural sources, saponification using a hot alkaline solution results in the breakdown of esters into free fatty alcohols and fatty acids in the final extract. Previous studies have shown that oleic acid-esterified policosanols exhibit greater absorption than both nonesterified forms and butyric acid-esterified policosanols, indicating higher bioavailability.

2. Traditional and Historical Use

Historically, octacosanol has been valued in traditional and folk medicine for its purported energizing and restorative properties. Early uses were often associated with its presence in wheat germ oil, a staple in health remedies throughout the 20th century, where it was believed to enhance stamina, improve heart health, and support the body's natural healing processes.

Scientific interest in octacosanol began in the mid-20th century when early studies suggested a potential to enhance exercise performance and stamina. During the mid-1900s, octacosanol gained popularity as a key ingredient in nutritional products aimed at athletes and individuals seeking improved physical performance. It was commonly used in remedies to combat fatigue, support cardiovascular health, and promote overall vitality.

Early work on the potential uses of octacosanol in the form of wheat germ oil is attributed to Thomas K. [curley], and octacosanol is derived primarily from wheat germ oil, as well as from krill, perilla, tomatoes, grape seed oil, sugarcane, and rice bran waxes. Policosanol (the mixture in which octacosanol is the primary component) was developed in Cuba, where the majority of the research — over 60 clinical trials — was carried out. This dietary supplement is a mixture of primary aliphatic alcohols whose main component is octacosanol, isolated from Cuban sugarcane wax.

Octacosanol isolated from the medicinal plant Holoptelea integrifolia (Ulmaceae) is believed to be an effective component for the prevention and treatment of various ailments. Research has explored octacosanol's role in lipid metabolism, with some clinical studies — especially from Cuba — showing that policosanol supplements could help reduce total and LDL cholesterol while increasing HDL cholesterol.

3. Key Constituents, Active Compounds, and Mechanisms of Action

Primary Active Compound

Octacosanol itself is the principal bioactive molecule under study. When taken as part of policosanol, the other long-chain alcohols (triacosanol, hexacosanol) may contribute additional or complementary activity, but octacosanol is considered the dominant pharmacologically active fraction.

Lipid Metabolism and Cholesterol-Lowering Mechanisms

Policosanol (with octacosanol as its main component) shows potential as an effective treatment for metabolic risk factors including dyslipidemia. It binds to the β-subunit of AMP-activated protein kinase (AMPK) and activates the AMPK pathway, which inhibits the activity of HMG-CoA reductase, leading to increased receptor-mediated uptake of LDL in the liver by increasing the number of hepatic LDL receptors.

Octacosanol supplementation decreases serum triacylglycerol concentration and enhances the concentration of serum fatty acids, probably through inhibition of hepatic phosphatidate phosphohydrolase. Although the activity of hormone-sensitive lipase was not influenced by octacosanol, higher activities of lipoprotein lipase in perirenal adipose tissue and total oxidation rate of fatty acids in muscle were observed.

Target prediction and molecular docking studies have identified PPARα and PPARδ as putative targets of octacosanol, guiding mechanistic analyses in adipose tissue. Both nonesterified octacosanol and oleic acid-esterified octacosanol enhanced lipolysis; nonesterified octacosanol preferentially increased fatty acid β-oxidation, whereas the esterified form specifically promoted thermogenic remodeling, indicating distinct metabolic consequences driven by ester chemistry.

Anti-Fatigue Mechanisms

A study designed to evaluate the antifatigue effect and molecular mechanism of octacosanol (200 mg/kg/day) in forced exercise-induced fatigue models of trained male C57BL/6 mice found that octacosanol ameliorated autonomic activities, forelimb grip strength, and swimming endurance; the levels of liver glycogen, muscle glycogen, blood lactic acid, lactate dehydrogenase, superoxide dismutase, and glutathione peroxidase were also regulated. Gene analysis results showed that treatment with octacosanol upregulated 29 genes and downregulated 38 genes in gastrocnemius tissue. Gene ontology analyses indicated that these genes enriched functions in relation to myofibril, contractile fiber, and calcium-dependent ATPase activity.

Antioxidant Mechanisms

Octacosanol fights against cellular stress by increasing glutathione level and thus scavenging reactive oxygen species. Octacosanol reduced liver injury by increasing glutathione (GSH) levels, and increased GSH contributes to stress tolerance.

Antiplatelet Mechanisms

Octacosanol, which has been studied mainly as a constituent of policosanol, may play a role in the management of dyslipidemia and may achieve antiplatelet effects similar to those of aspirin. Studies using policosanol with 50–60% octacosanol content have found effects on lipid metabolism and reduced platelet aggregation, as well as antiulcer and anti-inflammatory activity.

Neuroprotective Mechanisms

Oral administration of octacosanol significantly improved MPTP-induced behavioral impairments and decreased in tyrosine hydroxylase-positive neurons in the substantia nigra, suggesting protective effects against neurotoxicity. This neuroprotective effect may be mediated by blocking the phosphorylation of p38MAPK and JNK on the signal transduction pathway.

Octacosanol strikingly blocked the 6-OHDA-induced increased expression of the proNGF-p75NTR-sortilin death signaling complex and its downstream effector proteins. Through improvement of the oxidative-stress microenvironment and inhibition of apoptotic cell death, octacosanol's anti-parkinsonism effects may be associated with its inhibition of proNGF-p75NTR/sortilin-mediated cell death and activation of NGF-TrkA-mediated cell survival.

Vascular and Endothelial Mechanisms

Octacosanol has demonstrated enhanced proliferation and migration of human umbilical vein endothelial cells via activation of the PI3K/Akt and MAPK/Erk pathways.

Bioavailability

Despite the multi-target and multi-pathway biological activities of octacosanol, the key challenge in its practical application is its low oral bioavailability. Recent pharmacokinetic studies have shown that after gavage administration of octacosanol to Sprague-Dawley rats at a dose of 80 mg/kg body weight, the serum concentration of octacosanol at 1 hour was only 417 ng/mL and the liver level was 445 ng/g. This low bioavailability is primarily attributed to its poor water solubility caused by its highly hydrophobic nature and to inefficient intestinal absorption. Rat studies have found that the bioavailability of oral octacosanol ranges from 5% to 12% and that its half-life is 1–2 hours.

After ¹⁴C-octacosanol administration, radioactivity was mainly found in adipose tissue, especially in brown adipose tissue. Absorption was reportedly low and mainly excreted through feces. The radioactivity was also partly expired as ¹⁴CO₂, and about 49% of the administered dose was excreted through different pathways. Metabolites of octacosanol are present in the urine, and octacosanol may be partly oxidized and degraded to fatty acids through beta-oxidation.

4. Scientific Evidence by Area of Use

4.1 Lipid Profile and Cardiovascular Health

Overview: The cholesterol-modifying properties of octacosanol (studied primarily through its dominant role in policosanol) represent the most extensively investigated area of its potential therapeutic application.

Policosanol has garnered much attention in the literature because it has been reported to be as effective as statins for lowering cholesterol without any serious side effects. However, there is a significant amount of controversy surrounding this product, as most of the positive claims for its benefit come from the same group of Cuban researchers, and many of the results have been difficult to validate outside Cuba.

Human/Clinical Evidence: A 2019 study in the International Journal of Sports Physiology and Performance examined octacosanol directly in a human population. A total of 26 male taekwondo players were randomly divided into 2 groups: an experimental group performed a 5% weight-loss and taekwondo training program with 40 mg octacosanol intake (OCT; n = 13) for 6 days, and a control group performed the same weight-loss and taekwondo training program with a placebo (CON; n = 13). After 6 days of 5% weight loss through caloric restriction with high-intensity exercise training, participants who consumed octacosanol experienced significant improvements in HDL, LDL, and triglyceride levels when compared with the control group.

A double-blind, randomized, placebo-controlled study published in the Journal of Medical Biochemistry evaluated octacosanol added to statin therapy. This study aimed to evaluate the effects of octacosanol supplementation on markers of redox status in cardiovascular patients on chronic atorvastatin therapy. A double-blind, randomized, placebo-controlled, single-centre study was conducted. Octacosanol supplementation led to an improvement of lipid profile and markers of redox status in a responders' group. New studies are needed to validate these results in order to find the best approach for personalized supplementation as a useful adjunct to standard statin therapy.

Negative and Null Findings: Outside the Cuban research milieu, results have been mixed. Human trials using wheat germ-derived policosanol have not consistently replicated findings from Cuban sugarcane-derived policosanol. Quality clinical trial data are lacking to support use for any indication.

Evidence Strength: Preliminary to moderate. Sugarcane-derived policosanol (rich in octacosanol) showed positive results in Cuban trials; independent replication has been inconsistent. Direct human evidence for isolated octacosanol on lipids is limited to small studies.

4.2 Athletic Performance and Exercise Capacity

Overview: Octacosanol's potential as an ergogenic aid — improving endurance, reaction time, and physical strength — was among the earliest proposed uses, and remains an area of active but inconclusive investigation.

Octacosanol has been reported to exhibit antifatigue properties, antioxidant activities, cholesterol-lowering effects, cytoprotective function, and ergogenic properties. Studies have shown that the addition of dietary octacosanol has a beneficial effect on metabolic responses to submaximal cycle ergometry, grip and chest strength, and reaction time in human subjects.

In one preliminary trial, supplementation with 1 mg per day of octacosanol for eight weeks improved grip strength and visual reaction time, but it had no effect on chest strength, auditory reaction time, or endurance.

In the taekwondo player study, SOD (a marker of antioxidant capacity) was significantly increased in the octacosanol group after 6 days of training, while GPx (an antioxidant enzyme) was significantly reduced in the control group. MDA (a marker of lipid peroxidation) was also significantly increased in the control group, but not the octacosanol group. These results suggest that octacosanol can be used as a beneficial supplement for athletes who go through periods of caloric restriction with high-intensity exercise, as it was able to help protect against detrimental changes in cholesterol levels and oxidative stress.

Evidence Strength: Clinical trial data are lacking to support claims of enhanced athletic performance due to supplemental octacosanol intake. Very little human research has investigated the effects of octacosanol on exercise performance, and results have been mixed. The available studies are generally small, use varying doses and preparations, and lack standardized outcome measures. Animal evidence (mice, rats) is more extensive but cannot be directly extrapolated to humans.

4.3 Anti-Fatigue

As a functional anti-fatigue agent, octacosanol can enhance endurance and energy, eliminate pain in muscle cells, and improve body metabolic and myocardial functions, according to research conducted in cell and animal models.

A 2021 study in the Journal of Agricultural and Food Chemistry used a mouse model of exercise-induced fatigue to investigate the molecular mechanism. This study evaluated the antifatigue effect and molecular mechanism of octacosanol (200 mg/kg/day) in forced exercise-induced fatigue models of trained male C57BL/6 mice. Results showed that octacosanol ameliorated autonomic activities, forelimb grip strength, and swimming endurance, and regulated the levels of liver glycogen, muscle glycogen, blood lactic acid, lactate dehydrogenase, superoxide dismutase, and glutathione peroxidase.

Evidence Strength: Predominantly preclinical (animal models). There is a plausible biochemical rationale and supportive animal data, but well-controlled human trials demonstrating anti-fatigue effects of isolated octacosanol are lacking.

4.4 Stress and Sleep Modulation

A study published in Scientific Reports (2017) and indexed in PMC examined the effect of octacosanol on stress and sleep disturbance in mice. Cage change strategy was used to induce mild stress and sleep disturbance in mice, and effects of octacosanol administration on amount of sleep and stress were investigated. Results showed that octacosanol did not change rapid eye movement (REM) or non-REM (NREM) sleep compared to vehicle in normal mice. However, in the cage change experiment, octacosanol induced a significant increase in NREM sleep at doses of 100 and 200 mg/kg compared to vehicle, and decreased sleep latency. Octacosanol induced sleep by increasing the number of sleep episodes and decreasing wake episode duration. Plasma corticosterone levels were significantly reduced after octacosanol (200 mg/kg) administration, suggesting a decrease in stress level. Together, these data showed that, though octacosanol does not alter normal sleep, it clearly alleviates stress and restores stress-affected sleep.

Evidence Strength: Preclinical (murine). No human clinical trials are available to confirm these findings. The research is mechanistically interesting but cannot be applied directly to humans.

4.5 Neuroprotection and Parkinson's Disease

Although octacosanol has shown protective effects in rats with induced parkinsonism, clinical studies in humans have not documented these effects.

Two key preclinical studies have explored the anti-parkinsonian mechanisms of octacosanol. In a rat model of Parkinson's disease using 6-hydroxydopamine (6-OHDA): Oral administration of octacosanol (35–70 mg/kg for 14 days) significantly improved behavioral impairments in rats induced by 6-OHDA and dose-dependently preserved the free radical scavenging capability of the striatum. Octacosanol treatment also effectively ameliorated morphological appearances of tyrosine hydroxylase-positive neuronal cells in nigrostriatal systems and decreased apoptotic cells induced by 6-OHDA in the striatum.

In a complementary MPTP-treated mouse model: Oral administration of octacosanol (100 mg/kg) significantly improved behavioral impairments in mice treated by MPTP and markedly ameliorated morphological appearances of tyrosine hydroxylase-positive neuronal cells in the substantia nigra. Furthermore, octacosanol blocked MPTP-induced phosphorylation of p38MAPK and JNK, but not ERK1/2.

The limited available human evidence is historical and of low quality. One small study reported that octacosanol (15 mg daily of wheat germ oil taken for 6 weeks) improved subjectively rated scores in 3 of 10 patients with Parkinson's disease who were asked to rate themselves weekly based on activities of daily living and mood, endurance, and parkinsonism symptoms.

Evidence Strength: Animal evidence is consistent and mechanistically detailed, but robust human clinical trial data are absent. The protective anti-parkinsonian effect of octacosanol has been confirmed in MPTP-treated mouse models of Parkinson's disease. To the researchers' knowledge, this series of studies represents the first basic research on the neuroprotective effects of octacosanol in PD. Together with the evidence of protective effects on 6-OHDA-induced parkinsonism in rats, the studies strongly support the protective potential of octacosanol in animal models. Translation to human disease remains unproven.

4.6 Amyotrophic Lateral Sclerosis (ALS)

In the 1980s, small studies of octacosanol in patients with amyotrophic lateral sclerosis did not show clinically important improvement compared with placebo. Early research suggests that octacosanol does not improve symptoms of ALS.

Evidence Strength: Very weak; available human trials from the 1980s are small and show no significant benefit.

4.7 Anti-Inflammatory Activity

A 2026 study in Frontiers in Immunology investigated the cytoprotective role of octacosanol in lipopolysaccharide (LPS)-induced inflammation. Octacosanol (C₂₈H₅₈O) is a very-long-chain saturated aliphatic alcohol with 28 carbons and is the main component of policosanol. Policosanol in animal models is known to reduce atherosclerosis, but its mechanism of action remains unclear. This study investigated the pathways by which octacosanol alleviates LPS-induced inflammation in primary human aortic endothelial cells (HAECs). After overnight pretreatment with purified octacosanol, inflammation in HAECs was induced by lipopolysaccharide at 100 ng/ml. The effects of octacosanol on the levels of pro-inflammatory cytokines, and molecules involved in inflammation signaling, cell adhesion, and cell integrity were examined.

Evidence Strength: In vitro (cell culture) and animal model evidence only. No human clinical trials specifically on the anti-inflammatory effects of octacosanol have been published as of this writing.

4.8 Antioxidant Activity

Recent results have indicated that octacosanol may reduce oxidative stress in athletes during strength training. Taken together, octacosanol may reduce lipid peroxidation and improve the antioxidant capacity of mitochondria and prevent myocardial damage. These findings come partly from the randomized controlled statin/octacosanol trial described in Section 4.1.

4.9 Obesity and Metabolic Disorders

In mice, octacosanol and policosanol prevented high-fat diet–induced obesity and metabolic disorders by activating brown adipose tissue and improving hepatic lipid metabolism. Furthermore, oleic acid-esterified octacosanol enhanced adipose tissue thermogenesis by upregulating UCP1 and irisin, suggesting a dual role in promoting lipolysis and energy expenditure. While nonesterified and lauric acid-esterified forms also exhibited certain regulatory effects on adipose endpoints, their overall impact was moderate. These findings highlight the potential of octacosanol and its esterified counterpart as promising functional compounds for managing obesity-related lipid and cholesterol metabolism disorders.

Evidence Strength: Preclinical (high-fat diet murine models). No human trials on octacosanol for obesity or metabolic syndrome are available.

5. Body Systems and Health Areas Associated with Octacosanol

• Cardiovascular System: Lipid modulation (LDL reduction, HDL elevation, triglyceride reduction), antiplatelet activity, endothelial cell function, and potential anti-atherosclerotic effects.
• Musculoskeletal / Exercise Physiology: Anti-fatigue, improvement of grip strength, modulation of glycogen metabolism, and potential ergogenic effects.
• Central Nervous System: Neuroprotection in animal models of Parkinson's disease; stress reduction and restoration of stress-impaired sleep in murine models.
• Metabolic / Hepatic System: Modulation of lipid biosynthesis pathways via AMPK and HMG-CoA reductase; hepatoprotective effects through glutathione elevation.
• Immune and Inflammatory System: Anti-inflammatory activity in cell culture and animal models; reduction of pro-inflammatory cytokine expression in endothelial cells.
• Adipose Tissue: Activation of thermogenesis via UCP1 and irisin upregulation; enhancement of lipolysis and fatty acid β-oxidation.

6. Dosage Forms and Dosages Reported in Studies

Limited clinical trials have been conducted with octacosanol; data are lacking to provide firm dosing recommendations. The following dosages are drawn directly from published studies and should be understood in the context of the specific study populations and designs in which they were used:

• 1 mg per day of octacosanol for eight weeks was used in one preliminary trial examining grip strength and visual reaction time.
• 40 mg per day of octacosanol for 6 days was used in the taekwondo athlete study examining lipid profiles and oxidative stress.
• 15 mg daily of wheat germ oil (containing octacosanol) for 6 weeks was used in the small Parkinson's disease observational study.
• In one pharmacokinetic study, octacosanol 30 mg daily for 4 weeks did not result in measurable serum concentration changes.
• Human trials have used oral octacosanol in the range of approximately 15–50 mg per day, usually for several days to a few weeks.
• When octacosanol is taken as part of policosanol, 5–10 mg of policosanol is taken twice each day with meals. For exercise performance, 1 mg per day of octacosanol has been used in studies.
• In animal studies, doses used ranged from 35–70 mg/kg (oral, 14 days, rat PD model) to 100–200 mg/kg (mouse stress/sleep and anti-fatigue models) — these figures are not translatable to human doses without dedicated pharmacokinetic bridging studies.

7. Safety Considerations and Interactions

General Tolerability

Limited clinical trials have been conducted with octacosanol; however, a surveillance study of 2,252 elderly patients taking policosanol supplementation showed long-term tolerability. Policosanol is considered safe for humans because it is well tolerated and not associated with any adverse effects, even at single oral doses of 1,000 mg.

Research regarding the toxicity of octacosanol is limited; however, policosanol studies in rodents have reported no carcinogenicity or teratogenicity.

Anticoagulant and Antiplatelet Interactions

Case reports are lacking; however, because policosanol has the potential to inhibit platelet aggregation, the risk of hemorrhage exists. Concomitant anticoagulant therapy should be used cautiously. Octacosanol might slow blood clotting and increase the chance of bleeding in people with bleeding disorders.

Interaction with Levodopa/Carbidopa

Taking octacosanol along with levodopa/carbidopa might make Parkinson's disease symptoms worse. Octacosanol should not be taken if one is taking levodopa/carbidopa. This is a clinically important consideration given that octacosanol has been explored for potential anti-parkinsonian effects in animal models, yet the interaction with the primary human pharmacotherapy for Parkinson's disease is potentially adverse.

Blood Sugar and Antidiabetic Medication Interaction

Octacosanol might lower blood sugar levels. Taking octacosanol along with diabetes medications might cause blood sugar to drop too low.

Blood Pressure Medications

Octacosanol may also lower blood pressure. Medscape's interaction database lists octacosanol as increasing effects of multiple antihypertensive agents through pharmacodynamic synergism, though these interactions are generally classified as minor and of unknown clinical significance.

Perioperative Considerations

Octacosanol might slow blood clotting and reduce blood sugar levels, potentially increasing the risk of bleeding or very low blood sugar during and after surgery. Stopping octacosanol at least 2 weeks before a scheduled surgery has been recommended.

Pregnancy and Lactation

Information regarding safety and efficacy in pregnancy and lactation is lacking. In the absence of data, use during these periods is not supported by the available evidence base.

Regulatory Status

Octacosanol (as a dietary supplement) has not been reviewed by the FDA to determine whether it is safe or effective and is not subject to the quality standards and safety information collection standards that are applicable to most prescription drugs.

8. Summary of Evidence Quality

Across all proposed health areas, the overall body of human clinical evidence for isolated octacosanol is sparse and of modest quality. Translating biochemical effects into clear clinical outcomes in humans still requires larger, better-controlled trials. The strongest signals so far relate to modest improvements in cholesterol-related markers and oxidative stress in specific situations, with more tentative evidence in neurological and exercise performance domains. The largest body of work — that on policosanol and cholesterol — is substantially confounded by the geographic concentration of positive trials in Cuba and difficulties in independent replication. Preclinical (animal and cell culture) research is more extensive and demonstrates a plausible range of biological activities, but direct extrapolation to human clinical benefit remains premature without adequately powered randomized controlled trials.

References

• Taylor JC, Rapport L, Lockwood GB. "Octacosanol in human health." Nutrition. 2003;19(2):192–5. PubMed PMID: 12591561.
• Zrnić-Ćirić M, et al. "Association of octacosanol supplementation with redox status in patients on chronic statin therapy." Journal of Medical Biochemistry. 2023;42:47–57. PMC9921089.
• Wang T, et al. "Anti-parkinsonian effects of octacosanol in 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-treated mice." PMC4340021.
• Wang T, et al. "Protective effects of octacosanol on 6-hydroxydopamine-induced Parkinsonism in rats via regulation of ProNGF and NGF signaling." Acta Pharmacologica Sinica. 2010;31:765–74. PMC4007727.
• Kaushik MK, et al. "Octacosanol restores stress-affected sleep in mice by alleviating stress." Scientific Reports. 2017. PMC5566941.
• Kamchonemenukool S, et al. "Oleic Acid-Esterified Octacosanol as a Functional Ingredient to Counter Obesity-Associated Lipid Dysregulation through PPAR-Targeted Regulation." PMC12862754.
• Lee S, et al. "Improvement of Lipids and Reduction of Oxidative Stress With Octacosanol After Taekwondo Training." International Journal of Sports Physiology and Performance. 2019;14(9):1297–1303. PubMed PMID: 30958045.
• Zhou Y, et al. "Dietary Supplementation of Octacosanol Improves Exercise-Induced Fatigue and Its Molecular Mechanism." Journal of Agricultural and Food Chemistry. 2021;69(27):7603–7618.
• Yang X, et al. "Octacosanol and health benefits: Biological functions and mechanisms of action." Industrial Crops and Products. 2022. ScienceDirect.
• Review: "Octacosanol: Biological activities and bioavailability enhancement strategies." Food Chemistry. 2025. ScienceDirect.
• Frontiers in Immunology: "Cytoprotective role of octacosanol in lipopolysaccharide-induced inflammation." 2026.
• ScienceDirect Topics: "Octacosanol — an overview." ScienceDirect.
• Drugs.com Natural Products: "Octacosanol Uses, Benefits & Dosage." (References Taylor 2003, Fernández 2004, Kabir 1993/1995, and others.)
• WebMD Vitamins: "Octacosanol — Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews."
• PeaceHealth / TraceGains: "Octacosanol for Sports & Fitness."
• Shehata et al. "Multi-functional application of octacosanol as a feed additive in animal and aquaculture: A review." Journal of Animal Physiology and Animal Nutrition. 2024.
• Wikipedia: "1-Octacosanol."
• ResearchGate: "Wheat Germ Oil and Octacosanol" (Kabir Y, Kimura S, rat biodistribution studies 1993–1995).